The merger has closed and CRNX shares have been delisted. Shareholders should have already received or will soon receive the $85.00 per share cash consideration. There is no further trading opportunity in CRNX common stock. Monitor for any potential appraisal rights or post-closing adjustments, though none are indicated in this filing.
Price Chart
Executive Summary
Crinetics Pharmaceuticals has been acquired by Vertex Pharmaceuticals in an all-cash merger that closed on September 1, 2026. Each CRNX share was converted into the right to receive $85.00 per share in cash, for aggregate consideration of approximately $10.0 billion. The merger resulted in the delisting of CRNX from Nasdaq, the resignation of all incumbent directors and officers, and the adoption of new governing documents for the now-wholly-owned subsidiary.
Key Facts
- Vertex acquired Crinetics for $85.00 per share in cash, valuing the deal at approximately $10.0 billion.
- The merger closed on September 1, 2026, and CRNX common stock was delisted from the Nasdaq Global Select Market.
- All outstanding unvested stock options and RSUs vested immediately prior to the Effective Time.
- All eight incumbent directors resigned and were replaced by Charles Wagner as sole director.
- The company's certificate of incorporation and bylaws were amended and restated post-merger.
- Vertex funded the $10.0 billion consideration through cash on hand and borrowings under a term loan credit agreement.
- The 2018 Employee Stock Purchase Plan, the Sales Agreement with SVB Leerink and Cantor Fitzgerald, and three equity incentive plans were terminated in connection with the merger.
Financial Impact
Shareholders received $85.00 per share in cash, representing a total deal value of approximately $10.0 billion. Vertex funded the acquisition with cash on hand and debt.
Risk Factors
- No further upside for CRNX shareholders beyond the fixed $85.00 per share consideration.
- Potential for shareholder litigation related to the merger process or fairness of the price.
- Integration risk for Vertex in absorbing Crinetics' operations and pipeline.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (CRNX) — Batch item 1 | 0001140361-26-035195 |
| Document: ef20081409_8k.htm | 0001140361-26-035195 |
| Document: ef20081409_ex3-1.htm | 0001140361-26-035195 |
| Document: 0001140361-26-035195-index-headers.html | 0001140361-26-035195 |
| Document: 0001140361-26-035195-index.html | 0001140361-26-035195 |
| Document: 0001140361-26-035195.txt | 0001140361-26-035195 |
| 8-K Filing (CRNX) — Batch item 7 | 0001140361-26-035195 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | 15-12G | — | awaiting T+1 | — | — |
Sep 1, 2026 4w ago | 25-NSE | $84.95 $84.95 | · 0.00% | ▼ −0.44% | — |
Sep 1, 2026 4w ago | 8-K | $84.95 $84.95 | · 0.00% | ▼ −0.44% | — |
Aug 14, 2026 7w ago | 8-K | $84.70 $84.75 | ▲ +0.06% | ▲ +0.53% | — |
Aug 3, 2026 8w ago | Press Release | $83.86 $84.00 | ▲ +0.17% | ▲ +0.37% | — |
Jul 10, 2026 12w ago | DEFA14A | $83.67 $83.71 | ▲ +0.05% | ▼ −0.31% | — |
Jul 10, 2026 12w ago | 8-K | $83.67 $83.71 | ▲ +0.05% | ▼ −0.31% | — |
Jun 30, 2026 13w ago | Press Release | $38.68 $42.23 | ▲ +9.18% | ▲ +9.31% | — |
Jun 14, 2026 15w ago | Press Release | $35.12 $35.00 | ▼ −0.34% | ▲ +0.25% | — |
Jun 14, 2026 15w ago | Press Release | $35.12 $35.00 | ▼ −0.34% | ▲ +0.25% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access